Safety and Feasibility of Electrochemotherapy in the Treatment of Unresectable Liver Metastases From Colorectal Adenocarninoma
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 5
- 主要终点
- Safety and feasibility evaluation of Electrochemotherapy treatment of liver metastasesSafety and feasibility evaluation of Electrochemotherapy treatment of liver metastases as meaured by unexpected intraoperative adverse events
研究概览
简要总结
Electrochemotherapy (ECT) is a non-thermal tumour ablation modality. It consists of the local potentiation, by means of local reversible electroporation of tumour tissues, of the antitumor activity of non-permeant or poorly permeant anticancer drugs already possessing intrinsic cytotoxicity. ECT has proved to be effective in the treatment of various cutaneous tumour nodules of any origin. Mostly ECT is offered to patients in case of multiple cutaneous metastases, when they cannot be excised, due to their number or localization. This study investigate the application of ECT in the treatment of liver metastases from colorectal adenocarcinoma, for which other thermal cytoreductive methods would be risky compared to the supposed expected clinical benefits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients > 18 years of age
- •Histological confirmed colorectal adenocarcinoma
- •Histological or clinically confirmed metastatic colorectal adenocarcinoma lesions (liver lesions only are considered as metastatic disease) and not resecable.
- •A single liver lesion may not exceed 3 cm
- •Liver lesions must not have a depth greater than 2 cm from hepatic surface (Glisson Capsule) (measured clinically if possible otherwise on the basis of CT/ultrasound examination)
- •A life expectancy of at least 6 months.
- •Patients with a ECOG performance status < 2
- •Signed Informed Consent
- •Patient must be mentally capable of understanding the information given.
- •Patient must give informed consent.
排除标准
- •Age less than 18 years.
- •Patient pregnant or lactating (no contraceptive method is contraindicated, a pregnancy test will be administered to all women of childbearing age)
- •Life-threatening infection and/or heart failure and/or liver failure and/or other severe systemic pathologies that preclude laparotomy
- •Strumental analysis confirmed ascites.
- •Impaired kidney function.
- •Significant reduction in respiratory function.
- •Allergic reaction to bleomycin.
- •Coagulation disturbances
- •Patients with exclusion criteria for diagnostic MRI 3Tesla (with pace-makers and all those metal devices that are not compatible with 3T).
研究组 & 干预措施
electrochemotherapy
干预措施: Electrochemotherapy (Drug)
结局指标
主要结局
Safety and feasibility evaluation of Electrochemotherapy treatment of liver metastasesSafety and feasibility evaluation of Electrochemotherapy treatment of liver metastases as meaured by unexpected intraoperative adverse events
时间窗: 24 hours from Electrochemotherapy treatment
Safety and feasibility evaluation of Electrochemotherapy treatment of liver metastases as meaured by unexpected intraoperative adverse events and related postoperative complications.
次要结局
- Disease free survival(6 months from Electrochemotherapy treatment)
- Overall survival(6 months from Electrochemotherapy treatment)
- Quality of Life (Karnofsky performance status)(30 days and 6 months from ECT treatment)
- Objective response evaluation of treated liver metastases following RECIST criteria(30 days and 6 months from Electrochemotherapy treatment)
- Toxicity of Electrochemotherapy treatment of liver metastases as meaured by unexpected postoperative complications related to treatment(7 days)